Literature DB >> 7527464

Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibody.

E V Meulemans1, R Slobbe, P Wasterval, F C Ramaekers, G J van Eys.   

Abstract

A phage-display combinatorial library of VL and VH sequences of mouse antibodies was constructed, which contained 4.5 x 10(7) independent clones. From this library pools of phage were selected by up to four biopanning rounds on cytoskeletal preparations of ovarian carcinoma cells (OVCAR-3). Phage of these pools were then allowed to bind to a cytoskeleton preparation of bladder carcinoma cells (T24). The binding phage were challenged by a monoclonal antibody (mAb) directed against an epitope on cytokeratin 8. Displaced phage were rescued and screened for anti-cytokeratin immunoreactivity by ELISA, indirect immunofluorescence and Western blotting. About 50% of the phage selected by competition with the cytokeratin mAb reacted with the cytoskeletal preparations of T24 cells in ELISA. In contrast, in non-cytokeratin-containing cells, no reaction was observed. Immunofluorescence and Western blotting studies with a number of these clones showed reactivity against cytokeratin. We conclude that the phage-display competitive elution method can be used as a rapid technique to obtain immunoreactive phages, and eventually single-chain Fv (scFv) antibodies directed against defined epitopes, which were formerly characterized and validated by mAbs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527464     DOI: 10.1006/jmbi.1994.1735

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Phage antibodies obtained by competitive selection on complement-resistant Moraxella (Branhamella) catarrhalis recognize the high-molecular-weight outer membrane protein.

Authors:  E Boel; H Bootsma; J de Kruif; M Jansze; K L Klingman; H van Dijk; T Logtenberg
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

Review 3.  Selection of proteins and peptides from libraries displayed on filamentous bacteriophage.

Authors:  D McGregor
Journal:  Mol Biotechnol       Date:  1996-10       Impact factor: 2.695

4.  Phage-displayed peptide targeting on the Puumala hantavirus neutralization site.

Authors:  T Heiskanen; A Lundkvist; A Vaheri; H Lankinen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries.

Authors:  G Petersen; D Song; B Hügle-Dörr; I Oldenburg; E K Bautz
Journal:  Mol Gen Genet       Date:  1995-12-10

6.  A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.

Authors:  Rob C Roovers; Maria J W D Vosjan; Toon Laeremans; Rachid el Khoulati; Renée C G de Bruin; Kathryn M Ferguson; Arie J Verkleij; Guus A M S van Dongen; Paul M P van Bergen en Henegouwen
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

7.  Detection of TNT-derivatives with recombinant phages.

Authors:  Mladen Simonovicá; Branislav Simonovicá
Journal:  Bacteriophage       Date:  2012-04-01

8.  Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.

Authors:  Nika Strokappe; Agnieszka Szynol; Marlèn Aasa-Chapman; Andrea Gorlani; Anna Forsman Quigley; David Lutje Hulsik; Lei Chen; Robin Weiss; Hans de Haard; Theo Verrips
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

9.  Engineering the Single Domain Antibodies Targeting Receptor Binding Motifs Within the Domain III of West Nile Virus Envelope Glycoprotein.

Authors:  Jana Hruškovicová; Katarína Bhide; Patrícia Petroušková; Zuzana Tkáčová; Evelína Mochnáčová; Ján Čurlík; Mangesh Bhide; Amod Kulkarni
Journal:  Front Microbiol       Date:  2022-04-01       Impact factor: 6.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.